MGluR5 inhibitor

Biological Activity

ctep is a potent, long-acting, and orally bioavailable inhibitor of metabotropic glutamate receptor 5 (mglu5) with ic50 value of 11.4nm [1].ctep is a negative allosteric modulator of mglu5 and has inverse agonist activity. in the in vitro binding assay, ctep binds to human, mouse and rat mglu5 with kd values of 1.7nm, 1.8nm and 1.5 nm, respectively. in hek293 cells expressing mglu5, ctep inhibits quisqualate-induced ca2+ mobilization and inositol phosphate accumulation with ic50 value of 11.4nm and 6.4nm, respectively. in addition, it shows an ic50 value of 40.1nm in the ip accumulation assay, demonstrating its inverse agonist activity. ctep is proved to be a highly selective inhibitor of mglu5. it shows no significant activity against mglu1, mglu2, mglu3, mglu4, mglu6, mglu7 or mglu8 at concentration up to 10μm [1].in the in vivo vogel conflict drinking test, ctep markedly increases drinking time at doses of 0.3mg/kg. in adult c57bl/6 mice brain, ctep displaces the mglu5 antagonist abp688 in the regions expressing mglu5 by 50% at dose of 77.5 ng/g [1].

Biochem/physiol Actions

CTEP is a high-affinity, orally active, potent and selective metabotropic glutamate receptor 5 (mGlu5 or mGluR5) negative allosteric modulator (NAM) and inverse agonist (human/mouse/rat mGlu5 Kd = 1.7/1.8/1.5 nM; IC50 against quisqualate stimulation = 6.4/16.8/8/8 by IP accumulation or 11.4/42/4/6.9 by Ca2+ mobilization using human/mouse/rat mGlu5 HEK293 transfectants; IC50 = 40.1 nM against constitutive IP level in human mGlu5 HEK293) with >1000-fold selectivity over 103 molecular targets, including all known mGluRs. CTEP is an excellent tool compound for long-term in vivo studies (in mice and rats) with good pharmacokinetic properties (B/P ratio = 2.6, oral bioavailability ~100%, T1/2 ~18 hrs post 4.5 mg/kg p.o. in mice) and reported to display 30- to 100-fold higher in vivo potency than MPEP and fenobam in two rodent behavioral models sensitive to antianxiety drugs.

References

[1] lindemann l, jaeschke g, michalon a, et al. ctep: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. journal of pharmacology and experimental therapeutics, 2011, 339(2): 474-486.